Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T10:45:52.867Z Has data issue: false hasContentIssue false

Section 2 - Biological, Neurocognitive, and Medical Aspects

Published online by Cambridge University Press:  15 March 2019

Edited by
Carl I. Cohen  and
Paul D. Meesters
Carl I. Cohen
Affiliation:
SUNY Downstate Medical Center
Paul D. Meesters
Affiliation:
Friesland Mental Health Services
Get access
Type
Chapter
Information
Schizophrenia and Psychoses in Later Life
New Perspectives on Treatment, Research, and Policy
 , pp. 55 - 94
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Johnstone, E.C., Frith, C.D., Crow, T.J., Husband, J., Kreel, L.. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 308: 924–6, 1976.CrossRefGoogle Scholar
Weinberger, D.R., Torrey, E.F., Neophytides, A.N.. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 36: 735–39, 1979.CrossRefGoogle ScholarPubMed
Pearlson, G.D., Garbacz, D.J., Tompkins, R.H., et al. Lateral cerebral ventrical size in late onset schizophrenia. In Schizophrenia and Aging, ed. Miller, N. E., Cohen, G.D. New York: Guilford: 246–248, 1987.Google Scholar
De Leon, M.J., Ferris, S.H., George, A.E., et al. Computed tomography evaluations of brain-behavior relationships in senile dementia of the Alzheimer's type. Neurobiol Aging 1: 69–79, 1980.CrossRefGoogle ScholarPubMed
Naeser, M.A., Gebhardt, C., Levine, H.L.. Decreased computerized tomography numbers in patients with presenile dementia: detection in patients with otherwise normal scans. Arch Neurol 37: 401–9, 1980.CrossRefGoogle ScholarPubMed
Veroff, A.E., Pearlson, G.D., Ahn, H.S.. CT scan and neuropsychological correlates of Alzheimer's disease and Huntington's disease. Brain Cogn 1(2): 177–84, 1982.CrossRefGoogle ScholarPubMed
Seno, H., Shibata, M., Fujimoto, A., et al. Computed tomographic study of aged schizophrenic patients. Psychiatry Clin Neurosci 51(6): 373–7, 1997.CrossRefGoogle ScholarPubMed
Putnam, K.M., Harvey, P.D.. Cognitive impairment and enduring negative symptoms: a comparative study of geriatric and nongeriatric schizophrenia patients. Schizophr Bull 26(4): 867–78, 2000.CrossRefGoogle ScholarPubMed
Harvey, M.P., Moriarty, P.J., Friedman, J.I., et al. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biol Psychiatry 47(11): 962–8, 2000.CrossRefGoogle ScholarPubMed
Rossi, A., Bustini, M., Prosperini, P., et al. Neuromorphological abnormalities in schizophrenic patients with good and poor outcome. Acta Psychiatr Scand 101(2): 161–6, 2000.CrossRefGoogle ScholarPubMed
Tandon, R., DeQuardo, J.R., Taylor, S.F., et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45(3): 191–201, 2000.CrossRefGoogle ScholarPubMed
Mathalon, D.H., Sullivan, E.V., Lim, K.O., Pfefferbaum, A.. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 58(2): 148–57, 2001.CrossRefGoogle Scholar
Pearlson, G.D., Marsh, L.. Structural brain imaging in schizophrenia: a selective review. Biol Psychiatry 46: 627–49, 1999.CrossRefGoogle ScholarPubMed
Keshavan, M.S., Mulsant, B.H., Sweet, R.A., et al. MRI changes in schizophrenia in late life: a preliminary controlled study. Psych Res 60: 117–23, 1996.CrossRefGoogle ScholarPubMed
Koutsouleris, N., Davatzikos, C., Borgwardt, S., et al. Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders. Schizophr Bull 40(5): 1140–53, 2014.CrossRefGoogle ScholarPubMed
Cropley, V.L., Klauser, P., Lenroot, R.K., et al. Accelerated gray and white matter deterioration with age in schizophrenia. Am J Psychiatry 174(3): 286–295, 2017.CrossRefGoogle ScholarPubMed
Andreasen, N.C., Rezai, K., Alliger, R., et al. Hypofrontality in neuroleptic naïve patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49(12): 943–58, 1992.CrossRefGoogle ScholarPubMed
Buchsbaum, M.S., Hazlett, E.A.. Functional brain imaging and aging in schizophrenia. Schizophr Res 27(2-3): 129–41, 1997.CrossRefGoogle ScholarPubMed
Goldstein, P.C., Brown, G.G., Marcus, A., Ewing, J.R.. Effects of age, neuropsychological impairment and medication on regional cerebral blood flow in schizophrenia and major affective disorder. Henry Ford Hosp Med J 38(4): 202–6, 1990.Google ScholarPubMed
Dupont, L.P., Lehr, P.P., Lamoureaux, G., et al. Preliminary report: cerebral blood flow abnormalities in older schizophrenic patients. Psychiatry Res 55(3): 121–30, 1994.CrossRefGoogle ScholarPubMed
Harvey, P.D., Lombardi, J., Leibman, M., et al. Cognitive impairment and negative symptoms in geriatric chronic schizophrenia patients: a follow-up study. Schizophr Res (22): 223–31, 1996.CrossRefGoogle ScholarPubMed
Sheffield, J.M., Repovs, G., Harms, M.P., et al. Evidence for accelerated decline of functional brain network efficiency in schizophrenia. Schizophr Bull 42(3): 753–61, 2015.Google ScholarPubMed
Snitz, B.E., Macdonald, A.W., Carter, C.S.. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 32(1): 179–94, 2006.Google ScholarPubMed
Fallon, S.J., Williams-Gray, C.H., Barker, R.A., Owen, A.M., Hampshire, A.. Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. Cerebral Cortex 23(2): 361–9, 2013.CrossRefGoogle ScholarPubMed
Ira, E., Zanoni, M., Ruggeri, M., Dazzan, P., Tosato, S.. COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. J Psychiatry Neurosci 38(6): 366–80, 2013.CrossRefGoogle ScholarPubMed
Niizato, K., Genda, K., Nakamura, R., Iritani, S., Ikeda, K.. Cognitive decline in schizophrenics with Alzheimer's disease: a mini-review of neuropsychological and neuropathological studies. Prog Neuro-Psychopharmacol Biol Psychiatry 25(7): 1359–66, 2001.CrossRefGoogle ScholarPubMed
Thabit, H., Kennelly, S.M., Bhagarva, A., et al. Utilization of Frontal Assessment Battery and Executive Interview 25 in assessing for dysexecutive syndrome and its association with diabetes self-care in elderly patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 86(3): 208–12, 2009.CrossRefGoogle ScholarPubMed
Joober, R., Rouleau, G., Fon, E., et al. Apolipoprotein E genotype in schizophrenia. Am J Med Genet 67(2): 235, 1996.CrossRefGoogle ScholarPubMed
Liebers, D.T., Pirooznia, M., Seiffudin, F., et al. Polygenic risk of schizophrenia and cognition in a population-based survey of older adults. Schizophr Bull 42(4): 984–91, 2016.CrossRefGoogle Scholar
Mullins, N., Perroud, N., Uher, R., et al. Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study. Am J Med Genet B, Neuropsychiatric Genet 165B(5): 428–37, 2014.Google ScholarPubMed
Joseph, J., Depp, C., Martin, A.S., et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res 168(1–2): 456–60, 2015.CrossRefGoogle ScholarPubMed
Osler, M., Rostrup, E., Nordentoft, M., et al. Influence of early life characteristics on psychiatric admissions and impact of psychiatric disease on inflammatory biomarkers and survival: a Danish cohort study. World Psychiatry 14(3): 364–5, 2015.CrossRefGoogle ScholarPubMed
Lee, E.E., Hong, S., Martin, A.S., Eyler, L.T., Jeste, D.V.. Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. Am J Geriatr Psychiatry 25(1): 50–61, 2017.CrossRefGoogle ScholarPubMed
Czepielewski, L.S., Massuda, R., Panizzutti, B., et al. Telomere length and CCL11 levels are associated with gray matter volume and episodic memory performance in schizophrenia: evidence of pathological accelerated aging. Schizophr Bull 44(1): 158–67, 2018.CrossRefGoogle ScholarPubMed
Czepielewski, L.S., MassudaMassuda, R.R., Panizzutti, B.B., et al. Telomere length in subjects with schizophrenia, their unaffected siblings and healthy controls: evidence of accelerated aging. Schizophr Res 174(1–3): 39–42, 2016.CrossRefGoogle ScholarPubMed
Clementz, B.A., Sweeney, J.A., Hamm, J.P., et al. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry 173(4): 373–84, 2016.CrossRefGoogle ScholarPubMed
Arnold, S.E., Trojanowski, J.Q., Gur, R.E., et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 55(3): 225–32, 1998.CrossRefGoogle Scholar
Arnold, S.E., Trojanowski, J.Q.. Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Schizophr Bull 22(1): 5–9, 1996.CrossRefGoogle ScholarPubMed
Baldessarini, R.J., Hegarty, J.D., Bird, E.D., Benes, F.M.. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am J Psychiatry 154(6): 861–3, 1997.Google ScholarPubMed
Dwork, A.J., Susser, E.S., Keilp, J., et al. Senile degeneration and cognitive impairment in chronic schizophrenia. Am J Psychiatry 155(11): 1536–43, 1998.CrossRefGoogle ScholarPubMed
Radewicz, K., Garey, L.J., Gentleman, S.M., et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59(2): 137–50, 2000.CrossRefGoogle ScholarPubMed
Najjar, S., Pearlman, D.M.. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 161(1): 102–12, 2015.CrossRefGoogle ScholarPubMed
Volk, D.W. Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. Neurobiol Dis 99: 58–65, 2017.CrossRefGoogle ScholarPubMed
Laskaris, L.E., Di Biase, M.A., Everall, I., et al. Microglial activation and progressive brain changes in schizophrenia. Br J Pharmacol 173(4): 666–80, 2016.CrossRefGoogle ScholarPubMed
Bakhshi, K., Chance, S.A.. The neuropathology of schizophrenia: a selective review of past studies and emerging themes in brain structure and cytoarchitecture. Neuroscience 303: 82–102, 2015.CrossRefGoogle ScholarPubMed
Obuchowicz Bielecka-Wajdman, A.M., Paul-Samojedny, M., Nowacka, M.. Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: an in vitro study. Cytokine 94: 37–44, 2017.CrossRefGoogle Scholar
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12): 1209–23, 2005.CrossRefGoogle ScholarPubMed
Jones, P.B., Barnes, T.R., Davies, L., et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63(10): 1079–87, 2006.CrossRefGoogle Scholar
Lerner, P.P., Miodownik, C., Lerner, V.. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci 69(6): 321–34, 2015.CrossRefGoogle ScholarPubMed
Gerlach, J. Prevention/treatment of tardive dyskinesia. Acta Psychiatr Scand Suppl 291: 117–28, 1981.Google ScholarPubMed
Lencz, T., Malhotra, A.K.. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 11(4): 405–15, 2009.CrossRefGoogle ScholarPubMed
Woerner, M.G., Correll, C.U., Alvir, J.M., et al. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36(8): 1738–46, 2011.CrossRefGoogle ScholarPubMed
Woerner, M.G., Alvir, J.M., Saltz, B.L., et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155(11): 1521–8, 1998.CrossRefGoogle ScholarPubMed
Jeste, D.V., Caligiuri, M.P., Paulsen, J.S., et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52(9): 756–65, 1995.CrossRefGoogle ScholarPubMed
Lee, P.E., Sykora, K., Gill, S.S., et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 53(8): 1374–9, 2005.CrossRefGoogle ScholarPubMed
Woerner, M.G., Correll, C.U., Alvir, J.M., et al. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 36(8): 1738–46, 2011.CrossRefGoogle ScholarPubMed
Kinon, B.J., Kollack-Walker, S., Jeste, D., et al. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol 28(1): 67–79, 2015.CrossRefGoogle ScholarPubMed
O'Brien, A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry 31(7): 683–93, 2016.CrossRefGoogle ScholarPubMed
Byne, W., Stamu, C., White, L., et al. Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia. Int J Geriatr Psychiatry 15(1): 7–13, 2000.3.0.CO;2-Z>CrossRefGoogle Scholar
Dubovsky, S.I., Dubovsky, A.N.. Geriatric neuropsychopharmacology. In Textbook of Geriatric Neuropsychiatry, ed. Dubovsky, S.L., Buzan, R., Washington DC: The American Psychiatric Press: 800–1, 2000.Google Scholar
Volkow, N.D., Logan, J., Fowler, J.S., et al. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 157: 75–80, 2000.CrossRefGoogle ScholarPubMed
Seeman, P., Tinazzi, M.. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 44: 178–83, 2013.CrossRefGoogle ScholarPubMed
Miller, D.D., Andreasen, N.C., O'Leary, D.S., et al. Effect of antipsychotics on regional cerebral blood flow measured with positron emission tomography. Neuropsychopharmacology 17(4): 230–40, 1997.CrossRefGoogle ScholarPubMed
Gur, R.E., Maany, V., Mozley, P.D., et al. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 155(12): 1711–17, 1998.CrossRefGoogle ScholarPubMed
Corson, P.W., Nopoulos, P., Miller, D.D., Arndt, S., Andreasen, N.C.. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 156(8): 1200–4, 1999.CrossRefGoogle ScholarPubMed
Lang, D.J., Kopala, L.C., Vandorpe, R.A., et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry 158(4): 625–31, 2001.CrossRefGoogle ScholarPubMed
Hauser, R.A., Factor, S.A., Marder, S.R., et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 174(5): 476–84, 2017.CrossRefGoogle ScholarPubMed
Kenney, C., Hunter, C., Jankovic, J.. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 22(2): 193–7, 2007.CrossRefGoogle ScholarPubMed
Lett, T.A., Wallace, T.J., Chowdhury, N.I., et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17(3): 242–66, 2012.CrossRefGoogle ScholarPubMed
Mitchell, A.J., Vancampfort, D., Sweers, K., et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. Schizophr Bull 39(2): 306–18, 2013.Google ScholarPubMed
Jin, H., Folsom, D., Sasaki, A., et al. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res 125(2–3): 295–9, 2011.CrossRefGoogle ScholarPubMed
Guillemot-Legris, O., Muccioli, G.G.. Obesity-induced neuroinflammation: beyond the hypothalamus. Trends Neurosci 40(4): 237–53, 2017.CrossRefGoogle ScholarPubMed
Gohlke, J.M., Dhurandhar, E.J., Correll, C.U., et al. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Front Psychiatry 28(3): 62, 2012.Google Scholar

References

Cohen, C.I., Outcome of schizophrenia into later life: an overview. Gerontologist, 1990. 30(6): 790–7.CrossRefGoogle ScholarPubMed
Cohen, C.I., Directions for research and policy on schizophrenia and older adults: Summary of the GAP Committee report. Psychiatric Services, 2000. 51(3): 299–302.CrossRefGoogle ScholarPubMed
Gurland, B.J. and Cross, P.S., Epidemiology of psycho-pathology in old-age: some implications for clinical services. Psychiatric Clinics of North America, 1982. 5(1): 11–82.CrossRefGoogle Scholar
Palmer, B.W., Heaton, R.K., Paulsen, J.S., et al., Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology, 1997. 11(3): 437–46.CrossRefGoogle ScholarPubMed
Kahn, R.S. and Keefe, R.S.E., Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry, 2013. 70(10): 1107–12.CrossRefGoogle ScholarPubMed
Cuffel, B.J., Jeste, D.V., Halpain, M., et al., Treatment costs and use of community mental health services for schizophrenia by age cohorts. American Journal of Psychiatry, 1996. 153(7): 870–6.Google ScholarPubMed
Karim, S., Overshott, R., and Burns, A., Older people with chronic schizophrenia. Aging and Mental Health, 2005. 9(4): 315–324.CrossRefGoogle ScholarPubMed
Green, M.F. and Harvey, P.D., Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophrenia Bulletin, 2000. 26(1): 119–36.CrossRefGoogle ScholarPubMed
Kalache, S.M., Mulsant, B.H., Davies, S.J.C., et al., The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan. Schizophrenia Bulletin, 2015. 41(2): 374–81.CrossRefGoogle ScholarPubMed
Tsoutsoulas, C., Mulsant, B.H., Kalache, S.M., et al., The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. Schizophrenia Research, 2016. 170(2-3): 330–5.CrossRefGoogle ScholarPubMed
Roth, M., The natural history of mental disorder in old age. Journal of Mental Science, 1955. 101(423): 281–301.CrossRefGoogle ScholarPubMed
Holden, N.L., Late paraphrenia or the paraphrenias: a descriptive study with a 10-year follow-up. British Journal of Psychiatry, 1987. 150: 635–9.CrossRefGoogle ScholarPubMed
Folstein, M.F., Folstein, S.E., and McHugh, P.R., Mini-Mental State: practical method for grading cognitive state of patients for clinicians. Journal of Psychiatric Research, 1975. 12(3): 189–98.Google Scholar
Harvey, P.D., White, L., Parella, M., et al., The longitudinal stability of cognitive impairment in schizophrenia: Mini-Mental State scores at one- and two-year follow-ups in geriatric inpatients. British Journal of Psychiatry, 1995. 166: 630–3.CrossRefGoogle Scholar
Harvey, P.D., Lombardi, J., Leibman, M., et al., Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophrenia Research, 1996. 22(3): 223–31.CrossRefGoogle ScholarPubMed
Harvey, P.D., Lombardi, J., Leibman, M., , et al., Performance of chronic schizophrenic patients on cognitive neuropsychological measures sensitive to dementia. International Journal of Geriatric Psychiatry, 1996. 11(7): 621–7.3.0.CO;2-V>CrossRefGoogle Scholar
Harvey, P.D., Silverman, J.M., Mohs, R.C., et al., Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biological Psychiatry, 1999. 45(1): 32–40.CrossRefGoogle ScholarPubMed
Waddington, J.L. and Youssef, H.A., Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine, 1996. 26(4): 681–8.CrossRefGoogle Scholar
McGurk, S.R., Moriarty, P.J., Harvey, P.D., et al., The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophrenia Research, 2000. 42(1): 47–55.CrossRefGoogle ScholarPubMed
Friedman, J.I., Harvey, P.D., Coleman, T., et al., Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. American Journal of Psychiatry, 2001. 158(9): 1441–8.CrossRefGoogle ScholarPubMed
McClure, M.M., Barch, D.M., Flory, J.D., et al., Context-procesing deficits in schizotypal personality disorder. Journal of Abnormal Psychology, 2004. 113(4): 556–8.Google Scholar
Heaton, R.K., Gladsjo, J.A., Palmer, B.W., et al., Stability and course of neuropsychological deficits in schizophrenia. Archives of General Psychiatry, 2001. 58(1): 24–32.CrossRefGoogle ScholarPubMed
Savla, G.N., Moore, D.J., Roesch, S.C., et al., An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophrenia Research, 2006. 83(2-3): 215–23.Google Scholar
Palmer, B.W., Bondi, M.W., Twamley, E.W., et al., Are late-onset schizophrenia spectrum disorders neurodegenerative conditions? Annual rates of change on two dementia measures. Journal of Neuropsychiatry and Clinical Neurosciences, 2003. 15(1): 45–52.CrossRefGoogle ScholarPubMed
Laks, J., Fontenelle, L.F., Chalita, A., and Mendlowicz, M.V., Absence of dementia in late-onset schizophrenia: a one year follow-up of a Brazilian case series. Arquivos de Neuro-Psiquiatria, 2006. 64(4): 946–9.CrossRefGoogle ScholarPubMed
Brodaty, H., Sachdev, P., Koschera, A., et al., Long-term outcome of late-onset schizophrenia: 5-year follow-up study. British Journal of Psychiatry, 2003. 183: 213–19.CrossRefGoogle ScholarPubMed
Loewenstein, D.A., Czaja, S.J., Bowie, C.R., and Harvey, P.D., Age-associated differences in cognitive performance in older patients with schizophrenia: a comparison with healthy older adults. American Journal of Geriatric Psychiatry, 2012. 20(1): 29–40.CrossRefGoogle ScholarPubMed
Stern, Y., What is cognitive reserve? Theory and research application of the reserve concept. Journal of the International Neuropsychological Society, 2002. 8(3): 448–60.CrossRefGoogle ScholarPubMed
Harvey, P.D., Loewenstein, D.A., and Czaja, S.J., Hospitalization and psychosis: Influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiology of Disease, 2013. 53: 18–25.CrossRefGoogle ScholarPubMed
Thompson, W.K., Savla, G.N., Vahia, I.V., et al., Characterizing trajectories of cognitive functioning in older adults with schizophrenia: does method matter? Schizophrenia Research, 2013. 143(1): 90–6.CrossRefGoogle ScholarPubMed
Cohen, C.I. and Murante, T., A prospective analysis of the role of cognition in three models of aging and schizophrenia. Schizophrenia Research, 2018. 196: 22–8.CrossRefGoogle ScholarPubMed
Ribe, A.R., Laursen, T.M., Charles, M., et al., Long-term risk of dementia in persons with schizophrenia. JAMA Psychiatry, 2015. 72(11): 1095–101.CrossRefGoogle ScholarPubMed
Mattis, S., Dementia Rating Scale. 1973, Odessa, FL: Psychological Assessment Resources, Inc.Google Scholar
Randolph, C., Tierney, M.C., Mohr, E., and Chase, T.N., The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology, 1998. 20(3): 310–19.CrossRefGoogle ScholarPubMed
Almeida, O.P., Howard, R.J., Levy, R., et al., Cognitive features of psychotic states arising in late-life (late paraphrenia). Psychological Medicine, 1995. 25(4): 685–98.Google ScholarPubMed
Davidson, M., Harvey, P., Welsh, K.A., et al., Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. American Journal of Psychiatry, 1996. 153(10): 1274–9.Google ScholarPubMed
Harvey, P.D., Jacobsen, H., Mancini, D., et al., Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients. Schizophrenia Research, 2000. 43(1): 3–9.CrossRefGoogle ScholarPubMed
Jeste, D.V., Harris, M.J., Krull, A., et al., Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. American Journal of Psychiatry, 1995. 152(5): 722–30.Google ScholarPubMed
McBride, T., Moberg, P.J., Arnold, S.E., et al., Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease. Schizophrenia Research, 2002. 55(3): 217–27.CrossRefGoogle ScholarPubMed
Miller, B.L., Lesser, I.M., Boone, K.B., et al., Brain-lesions and cognitive function in late-life psychosis. British Journal of Psychiatry, 1991. 158: 76–82.CrossRefGoogle ScholarPubMed
Moore, D.J., Palmer, B.W., and Jeste, D.V., Use of the Mini-Mental State Exam in middle-aged and older outpatients with schizophrenia: cognitive impairment and its associations. American Journal of Geriatric Psychiatry, 2004. 12(4): 412–19.Google ScholarPubMed
Patterson, T.L., Klapow, J.C., Eastham, J.H., et al., Correlates of functional status in older patients with schizophrenia. Psychiatry Research, 1998. 80(1): 41–52.CrossRefGoogle ScholarPubMed
Sachdev, P., Brodaty, H., Rose, N., and Cathcart, S., Schizophrenia with onset after age 50 years 2: Neurological, neuropsychological and MRI investigation. British Journal of Psychiatry, 1999. 175: 416–21.CrossRefGoogle ScholarPubMed
Sachdev, P., Brodaty, H., Cheang, D., and Cathcart, S., Hippocampus and amygdala volumes in elderly schizophrenic patients as assessed by magnetic resonance imaging. Psychiatry and Clinical Neurosciences, 2000. 54(1): 105–12.CrossRefGoogle ScholarPubMed
Rajji, T.K., Voineskos, A.N., Butters, M.A., et al., Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS Consensus Cognitive Battery. American Journal of Geriatric Psychiatry, 2013. 21(2): 108–18.CrossRefGoogle ScholarPubMed
Bankole, A.O., Cohen, C.I., Vahia, I., et al., Factors affecting quality of life in a multiracial sample of older persons with schizophrenia. American Journal of Geriatric Psychiatry, 2007. 15(12): 1015–23.CrossRefGoogle Scholar
Cohen, C.I., Stastny, P., Perlick, D., Samuelly, I., and Horn, L., Cognitive deficits among aging schizophrenic-patients residing in the community. Hospital and Community Psychiatry, 1988. 39(5): 557–9.Google ScholarPubMed
Evans, J.D., Negron, A.E., Palmer, B.W., et al., Cognitive deficits and psychopathology in institutionalized versus community-dwelling elderly schizophrenia patients. Journal of Geriatric Psychiatry and Neurology, 1999. 12(1): 11–15.CrossRefGoogle ScholarPubMed
Palmer, B.W., Dunn, L.B., Appelbaum, P.S., and Jeste, D.V., Correlates of treatment-related decision-making capacity among middle-aged and older patients with schizophrenia. Archives of General Psychiatry, 2004. 61(3): 230–6.CrossRefGoogle ScholarPubMed
Zorrilla, L.T.E., Heaton, R.K., McAdams, L.A., et al., Cross-sectional study of older outpatients with schizophrenia and healthy comparison subjects: no differences in age-related cognitive decline. American Journal of Psychiatry, 2000. 157(8): 1324–6.Google Scholar
Jeste, D.V., Palmer, B.W., Appelbaum, P.S., et al., A new brief instrument for assessing decisional capacity for clinical research. Archives of General Psychiatry, 2007. 64(8): 966–74.CrossRefGoogle ScholarPubMed
Evans, J.D., Heaton, R.K., Paulsen, J.S., et al., The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biological Psychiatry, 2003. 53(5): 422–30.CrossRefGoogle ScholarPubMed
Fucetola, R., Seidman, L.J., Kremen, W.S., et al., Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biological Psychiatry, 2000. 48(2): 137–46.CrossRefGoogle ScholarPubMed
Depp, C.A., Moore, D.J., Sitzer, D., et al., Neurocognitive impairment in middle-aged and older adults with bipolar disorder: comparison to schizophrenia and normal comparison subjects. Journal of Affective Disorders, 2007. 101(1–3): 201–9.CrossRefGoogle ScholarPubMed
Heaton, R., Paulsen, J.S., McAdams, L.A., et al., Neuropsychological deficits in schizophrenics: relationship to age, chronicity, and dementia. Archives of General Psychiatry, 1994. 51(6): 469–76.CrossRefGoogle ScholarPubMed
Kosmidis, M.H., Bozikas, V.P., Vlahou, C.H., et al., Verbal fluency in institutionalized patients with schizophrenia: age-related performance decline. Psychiatry Research, 2005. 134(3): 233–40.CrossRefGoogle ScholarPubMed
Moore, R., Blackwood, N., Corcoran, R., et al., Misunderstanding the intentions of others: an exploratory study of the cognitive etiology of persecutory delusions in very late-onset schizophrenia-like psychosis. American Journal of Geriatric Psychiatry, 2006. 14(5): 410–18.CrossRefGoogle ScholarPubMed
Dickinson, D., Ramsey, M.E., and Gold, J.M., Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of General Psychiatry, 2007. 64(5): 532–42.CrossRefGoogle ScholarPubMed
Ting, C., Rajji, T.K., Ismail, Z., et al., Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late life. PLOS One, 2010. 5(4): e10151.CrossRefGoogle ScholarPubMed
Green, M.F., What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 1996. 153(3): 321–30.Google ScholarPubMed
Lewandowski, K.E., Cohen, B.M., Keshavan, M.S., Sperry, S.H., and Ongür, D., Neuropsychological functioning predicts community outcomes in affective and non-affective psychoses: a 6-month follow-up. Schizophrenia Research, 2013. 148(1–3): 34–7.CrossRefGoogle ScholarPubMed
Tabares-Seisdedos, R., Balanzá-Martínez, V., Sánchez-Moreno, J., et al., Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. Journal of Affective Disorders, 2008. 109(3): 286–99.CrossRefGoogle ScholarPubMed
Arts, B., Jabben, N., Krabbendam, L., and van Os, J., A 2-year naturalistic study on cognitive functioning in bipolar disorder. Acta Psychiatrica Scandinavica, 2011. 123(3): 190–205.CrossRefGoogle Scholar
Nemoto, T., Niimura, H., Ryu, Y., Sakuma, K., and Mizuno, M., Long-term course of cognitive function in chronically hospitalized patients with schizophrenia transitioning to community-based living. Schizophrenia Research, 2014. 155(1–3): 90–5.CrossRefGoogle ScholarPubMed
Kennedy, J., Jeste, D., Kaiser, C.J., et al., Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. International Journal of Geriatric Psychiatry, 2003. 18(11): 1013–20.CrossRefGoogle ScholarPubMed
Harvey, P.D., Napolitano, J.A., Mao, L., and Gharabawi, G., Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. International Journal of Geriatric Psychiatry, 2003. 18(9): 820–8.CrossRefGoogle ScholarPubMed
Jeste, D.V., Barak, Y., Madhusoodanan, S., Grossman, F., and Gharabawi, G., International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. American Journal of Geriatric Psychiatry, 2003. 11(6): 638–47. [Erratum appears in American Journal of Geriatric Psychiatry, 2004. 12(1): 49].CrossRefGoogle ScholarPubMed
Kasckow, J., Lanouette, N., Patterson, T., et al., Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: Effect on functioning. International Journal of Geriatric Psychiatry, 2010. 25(2): 183–90.CrossRefGoogle ScholarPubMed
Rajji, T.K., Mulsant, B.H., Nakajima, S., et al., Cognition and dopamine D-2 receptor availability in the striatum in older patients with schizophrenia. American Journal of Geriatric Psychiatry, 2017. 25(1): 1–10.CrossRefGoogle ScholarPubMed
Golas, A.C., Kalache, S.M., Tsoutsoulas, C., et al., Cognitive remediation for older community-dwelling individuals with schizophrenia: a pilot and feasibility study. International Journal of Geriatric Psychiatry, 2015. 30(11): 1129–34.CrossRefGoogle ScholarPubMed
McGurk, S.R. and Mueser, K.T., Response to cognitive rehabilitation in older versus younger persons with severe mental illness. American Journal of Psychiatric Rehabilitation, 2008. 11: 90–105.CrossRefGoogle Scholar
Wykes, T., Reeder, C., Landau, S., et al., Does age matter? Effects of cognitive rehabilitation across the age span. Schizophrenia Research, 2009. 113(2–3): 252–8.CrossRefGoogle ScholarPubMed
Chan, C.L., Ngai, E.K., Leung, P.K., and Wong, S., Effect of the adapted virtual reality cognitive training program among Chinese older adults with chronic schizophrenia: a pilot study. International Journal of Geriatric Psychiatry, 2010. 25(6): 643–9.CrossRefGoogle ScholarPubMed
Kontis, D., Huddy, V., Reeder, C., Landau, S., and Wykes, T., Effects of age and cognitive reserve on cognitive remediation therapy outcome in patients with schizophrenia. American Journal of Geriatric Psychiatry, 2013. 21(3): 218–30.CrossRefGoogle ScholarPubMed
Granholm, E., McQuaid, J.R., McClure, F.S., et al., A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. The American Journal of Psychiatry, 2005. 162(3): 520–9.CrossRefGoogle ScholarPubMed
Granholm, E., McQuaid, J.R., McClure, F.S., et al., Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. Journal of Clinical Psychiatry, 2007. 68(5): 730–7.Google Scholar
Granholm, E., McQuaid, J.R., Link, P.C., et al., Neuropsychological predictors of functional outcome in cognitive behavioral social skills training for older people with schizophrenia. Schizophrenia Research, 2008. 100(1–3): 133–143.CrossRefGoogle ScholarPubMed
Cohen, C.I. and Iqbal, M., Longitudinal study of remission among older adults with schizophrenia spectrum disorder. American Journal of Geriatric Psychiatry, 2014. 22(5): 450–8.CrossRefGoogle ScholarPubMed
Shmukler, A.B., Gurovich, I.Y., Agius, M., and Zaytseva, Y., Long-term trajectories of cognitive deficits in schizophrenia: a critical overview. European Psychiatry, 2015. 30(8): 1002–10.CrossRefGoogle ScholarPubMed

References

Hendrie, HC, Tu, W, Tabbey, R, et al. Health outcomes and cost of care among older adults with schizophrenia: a 10-year study using medical records across the continuum of care. Am J Geriatr Psychiatry 2014; 22(5): 427–36.CrossRefGoogle ScholarPubMed
Brink, M, Green, A, Bojesen, AB, et al. Physical health, medication, and healthcare utilization among 70–year–old people with schizophrenia: a nationwide Danish register study. Am J Geriatr Psychiatry 2017; 25: 500–9.CrossRefGoogle ScholarPubMed
Talaslahti, T, Alanen, H-M, Hakko, H, et al. Mortality and causes of death in older patients with schizophrenia. Int J Geriatr Psychiatry 2012; 27: 1131–7.CrossRefGoogle ScholarPubMed
Laursen, TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011; 131(1–3): 101–4.CrossRefGoogle ScholarPubMed
Hjorthøj, C, Stürup, AE, Mcgrath, JJ, Nordentoft, M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4(4): 295–301.CrossRefGoogle ScholarPubMed
Saha, S, Chant, D, McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123–31.CrossRefGoogle ScholarPubMed
Cohen, CI, Freeman, K, Ghoneim, D, et al. Advances in the conceptualization and study of schizophrenia in later life. Psychiatr Clin N Am 2018; 41: 39–53.CrossRefGoogle ScholarPubMed
Almeida, OP, Hankey, GJ, Yeap, BB, et al. Mortality among people with severe mental disorders who reach old age: a longitudinal study of a community-representative sample of 37892 men. PloS one 2014; 9(10): e111882.CrossRefGoogle ScholarPubMed
Meesters, PD, Comijs, HC, Smit, JH, et al. Mortality and its determinants in late-life schizophrenia: a 5-year prospective study in a Dutch catchment area. Am J Geriatr Psychiatry 2016; 24: 272–7.CrossRefGoogle Scholar
Hoang, U, Stewart, R, Goldacre, MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ 2011; 343: d5422.CrossRefGoogle ScholarPubMed
Erlangsen, A, Eaton, WW, Mortensen, PB, Conwell, Y. Schizophrenia: a predictor of suicide during the second half of life? Schizophr Res 2012; 134(2–3): 111–17.CrossRefGoogle ScholarPubMed
Chang, CK, Hayes, RD, Broadbent, M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 2010; 10: 77.CrossRefGoogle ScholarPubMed
Meesters, PD. Healthy older schizophrenia patients: exceptions to the rule? Am J Geriatr Psychiatry 2017; 25(5): 510–11.CrossRefGoogle ScholarPubMed
Crump, C, Winkleby, MA, Sundquist, K, Sundquist, J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013; 170(3): 324–33.CrossRefGoogle ScholarPubMed
Partti, K, Vasankari, T, Kanervisto, M, et al. Lung function and respiratory diseases in people with psychosis: population-based study. Br J Psychiatry 2015; 207(1): 37–45.CrossRefGoogle ScholarPubMed
Kredentser, MS, Martens, PJ, Chochinov, HM, Prior, HJ. Cause and rate of death in people with schizophrenia across the lifespan: a population-based study in Manitoba, Canada. J Clin Psychiatry 2012; 74: 154–61.Google Scholar
Talaslahti, T, Alanen, HM, Hakko, H, et al. Patients with very‐late‐onset schizophrenia‐like psychosis have higher mortality rates than elderly patients with earlier onset schizophrenia. Int J Geriatr Psychiatry 2015; 30(5): 453–9.CrossRefGoogle ScholarPubMed
Hsu, J-H, Chien, IC, Lin, CH, Chou, YJ, Chou, P. Increased risk of chronic obstructive pulmonary disease in patients with schizophrenia: a population-based study. Psychosomatics 2013; 54(4): 345–51.CrossRefGoogle ScholarPubMed
Schoepf, D, Uppal, H, Potluri, R, Heun, R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci 2014; 264(1): 3–28.CrossRefGoogle ScholarPubMed
Bouza, C, López-Cuadrado, T, María Amate, J. Physical disease in schizophrenia: a population-based analysis in Spain. BMC Publ Health 2010; 10(1): 745.CrossRefGoogle ScholarPubMed
Cahoon, EK, McGinty, EE, Ford, DE, Daumit, GL. Schizophrenia and potentially preventable hospitalizations in the United States: a retrospective cross-sectional study. BMC Psychiatry 2013; 13(1): 37.CrossRefGoogle ScholarPubMed
Olfson, M, Gerhard, T, Huang, C, Crystal, S, Stroup, TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72(12): 1172–81.CrossRefGoogle ScholarPubMed
Chen, Y-H, Lin, H-C, Lin, H-C. Poor clinical outcomes among pneumonia patients with schizophrenia. Schizophr Bull 2010; 37(5): 1088–94.Google ScholarPubMed
Chou, FH-C, Tsai, K-Y, Chou, Y-M. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study. J Psychiatr Res 2013; 47(4): 460–6.CrossRefGoogle ScholarPubMed
U.S. Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioural Disturbances. Silver Spring, MD: U.S. Food and Drug Administration; 2005.Google Scholar
Trifirò, G, Gambassi, G, Sen, EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010; 152: 418–25.CrossRefGoogle ScholarPubMed
Knol, W, Marum, RJ, Jansen, PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56: 661–6.CrossRefGoogle ScholarPubMed
Gau, JT, Acharya, U, Khan, S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010; 10: 45.CrossRefGoogle ScholarPubMed
Star, K, Bate, A, Meyboom, RH, Edwards, IR. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract 2010; 60: e385–94.CrossRefGoogle ScholarPubMed
Barnett, MJ, Perry, PJ, Alexander, B, Kaboli, PJ. Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol 2006; 26: 182–7.CrossRefGoogle ScholarPubMed
Kuo, C-J, Yang, S-Y, Liao, Y-T, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39(3): 648–57.CrossRefGoogle ScholarPubMed
Trifirò, G. Antipsychotic drug use and community-acquired pneumonia. Curr Infect Disease Rep 2011; 13(3): 262–8.Google ScholarPubMed
Correll, CU, Detraux, J, De Lepeleire, J, De Hert, M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14(2): 119–36.CrossRefGoogle ScholarPubMed
Vahia, IV, Diwan, S, Bankole, AO, et al. Adequacy of medical treatment among older persons with schizophrenia. Psychiatr Serv 2008; 59: 853–9.CrossRefGoogle ScholarPubMed
Kilbourne, AM, Brar, JS, Drayer, RA, Xu, X, Post, EP. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007; 48(5): 412–17.CrossRefGoogle ScholarPubMed
Sajatovic, M, Gunzler, D, Einstadter, D, et al. A preliminary analysis of individuals with serious mental illness and comorbid diabetes. Arch Psychiatr Nurs 2016; 30(2): 226–9.CrossRefGoogle ScholarPubMed
Osborn, DPJ, Levy, G, Nazareth, I, Petersen, I, Islam, A, King, MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007; 64(2): 242–9.CrossRefGoogle Scholar
Casey, DA, Rodriguez, M, Northcott, C, Vickar, G, Shihabuddin, L. Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med 2011; 41(3): 245–51.CrossRefGoogle ScholarPubMed
Martens, PJ, Chochinov, HM, Prior, HJ. Where and how people with schizophrenia die: a population-based, matched cohort study in Manitoba, Canada. J Clin Psychiatry 2013; 74(6): e551–7.CrossRefGoogle Scholar
Jeste, DV, Wolkowitz, OM, Palmer, BW. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull 2011; 37(3): 451–5.CrossRefGoogle ScholarPubMed
Bresee, LC, Majumdar, SR, Patten, SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117: 75–82.CrossRefGoogle ScholarPubMed
Hahn, LA, Mackinnon, A, Foley, DL, et al. The value of counting WHO-defined cardiovascular risk factors for death and disability in a national sample of adults with psychosis. Schizophr Res 2017; 182: 13–18.CrossRefGoogle Scholar
Fors, BM, Isacson, D, Bingefors, K, Widerlov, B. Mortality among persons with schizophrenia in Sweden: an epidemiological study. Nord J Psychiatry 2007; 61(4): 252–9.CrossRefGoogle ScholarPubMed
Goff, DC, Cather, C, Evins, AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005; 66(2): 183–94.CrossRefGoogle ScholarPubMed
Olfson, M, Gerhard, T, Huang, C, Crystal, S, Stroup, TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72(12): 1172–81.CrossRefGoogle ScholarPubMed
Ösby, U, Westman, J, Hällgren, J, Gissler, M. Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987–2010. Eur J Publ Health 2016; 26(5): 867–71.CrossRefGoogle ScholarPubMed
Schulman-Marcus, J, Goyal, P, Swaminathan, RV, et al. Comparison of trends in incidence, revascularization, and in-hospital mortality in ST-elevation myocardial infarction in patients with versus without severe mental illness. Am J Cardiol 2016; 117(9): 1405–10.CrossRefGoogle ScholarPubMed
Bodén, R, Molin, E, Jernberg, T, et al. Higher mortality after myocardial infarction in patients with severe mental illness: a nationwide cohort study. J Intern Med 2015; 277(6): 727–36.CrossRefGoogle ScholarPubMed
Viñas, CL, Fernández San-Martín, MI, Martín López, LM. Effectiveness of a joint project between primary care and mental health to improve the recording of cardiovascular risk factors in patients with psychosis. Aten Primaria 2012; 45(6): 307–14.Google Scholar
Rouillon, F, Van Ganse, E, Vekhoff, P, et al. Vigilance level for cardiovascular risk factors in schizophrenic patients. L'Encephale 2015; 41(1): 70–7.Google ScholarPubMed
Daumit, GL, Goff, DC, Meyer, JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008; 105(1–3): 174–87.CrossRefGoogle ScholarPubMed
Torniainen, M, Mittendorfer-Rutz, E, Tanskanen, A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41(3): 656–63.CrossRefGoogle ScholarPubMed
Zhou, C, Tao, R, Jiang, R, Lin, X, Shao, M. Cancer mortality in patients with schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2017; 211(1): 7–13.CrossRefGoogle Scholar
Talaslahti, T. Finnish older patients with schizophrenia: antipsychotic use, psychiatric admissions, long-term care and mortality. Dissertation, University of Tampere, 2015.Google Scholar
Kelly, DL, McMahon, RP, Wehring, HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull 2011; 37(4): 832–8.CrossRefGoogle ScholarPubMed
Das-Munshi, J, Chang, CK, Dutta, R, et al. Ethnicity and excess mortality in severe mental illness: a cohort study. Lancet Psychiatry 2017; 4(5): 389–99.Google ScholarPubMed
Kisely, S, Sadek, J, Mackenzie, A, Lawrence, D, Campbell, LA. Excess cancer mortality in psychiatric patients. Can J Psychiatry 2008; 53: 753–61.CrossRefGoogle ScholarPubMed
Kisely, S, Crowe, E, Lawrence, D. Cancer-related mortality in people with mental illness. JAMA Psychiatry 2013; 70(2): 209–17.CrossRefGoogle ScholarPubMed
Lawrence, D, Holman, CD, Jablensky, AV, Threlfall, TJ, Fuller, SA. Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand 2000; 101(5): 382–8.CrossRefGoogle ScholarPubMed
Bushe, CJ, Hodgson, R. Schizophrenia and cancer: in 2010 do we understand the connection? Can J Psychiatry 2010; 55(12): 761–7.CrossRefGoogle ScholarPubMed
Goldacre, MJ, Kurina, LM, Wotton, CJ, Yeates, D, Seagroat, V. Schizophrenia and cancer: an epidemiological study. Br J Psychiatry 2005; 187: 334–8.CrossRefGoogle ScholarPubMed
Chen, LY, Hung, YN, Chen, YY, et al. Cancer incidence in young and middle-aged people with schizophrenia: nationwide cohort study in Taiwan, 2000–2010. Epidemiol Psychiatr Sci 2018; 27(2): 146–56.CrossRefGoogle Scholar
Lin, G-M, Chen, YJ, Kuo, DJ, et al. Cancer incidence in patients with schizophrenia or bipolar disorder: a nationwide population-based study in Taiwan, 1997–2009. Schizophr Bull 2013; 39(2): 407–16.CrossRefGoogle ScholarPubMed
Kisely, S, Forsyth, S, Lawrence, D. Why do psychiatric patients have higher cancer mortality rates when cancer incidence is the same or lower? Aus NZ J Psychiatry 2016; 50(3): 254–63.CrossRefGoogle ScholarPubMed
Lin, C‐Y, Lane, HY, Chen, TT, et al. Inverse association between cancer risks and age in schizophrenic patients: a 12‐year nationwide cohort study. Cancer Sci 2013; 104(3): 383–90.CrossRefGoogle ScholarPubMed
Bergamo, C, Sigel, K, Mhango, G, Kale, M, Wisnivesky, JP. Inequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study. Psychosom Med 2014; 76(3): 215.CrossRefGoogle ScholarPubMed
Baillargeon, J, Kuo, YF, Lin, YL, et al. Effect of mental disorders on diagnosis, treatment, and survival of older adults with colon cancer. J Am Geriatr Soc 2011; 59(7): 1268–73.CrossRefGoogle ScholarPubMed
Werneke, U, Horn, O, Maryon-Davis, A, et al. Uptake of screening for breast cancer in patients with mental health problems. J Epidemiol Community Health 2006; 60(7): 600–5.CrossRefGoogle ScholarPubMed
Irwin, KE, Henderson, DC, Knight, HP, Pirl, WF. Cancer care for individuals with schizophrenia. Cancer 2014; 120(3): 323–34.CrossRefGoogle ScholarPubMed
Aggarwal, A, Pandurangi, A, Smith, W. Disparities in breast and cervical cancer screening in women with mental illness: a systematic literature review. Am J Prev Med 2013; 44(4): 392–8.CrossRefGoogle ScholarPubMed
Chochinov, H, Martena, PJ, Prior, HJ, Fransoo, R, Burland, E. Does a diagnosis of schizophrenia reduce rates of mammography screening? A Manitoba population-based study. Schizophr Res 2009; 113: 95–100.CrossRefGoogle ScholarPubMed
Xiong, G, Bermudes, R, Torres, S, Hales, R. Use of cancer screening services among patients with serious mental illness in Sacramento County. Psychiatr Serv 2008; 59: 929–32.CrossRefGoogle Scholar
Martens, PJ, Chochinov, HM, Prior, HJ, et al. Are cervical cancer screening rates different for women with schizophrenia? A Manitoba population-based study. Schizophr Res 2009; 113(1): 101–6.CrossRefGoogle ScholarPubMed
Crump, C, Winkleby, MA, Sundquist, K, Sundquist, J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013; 170: 324–33.CrossRefGoogle ScholarPubMed
De Hert, M, Peuskens, J, Sabbe, T, et al. Relationship between prolactin, breast cancer risk and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 2016; 133(1): 5–22.CrossRefGoogle ScholarPubMed
Andrews, AO, Bartels, SJ, Xie, H, et al. Increased risk of nursing home admission among middle aged and older adults with schizophrenia. Am J Geriatr Psychiatry 2009; 17(8): 697–705.CrossRefGoogle ScholarPubMed
Horan, ME, Muller, JJ, Winocur, S, et al. Quality of life in boarding houses and hostels: a residents’ perspective. Community Ment Health J 2001; 37(4): 323–34.CrossRefGoogle ScholarPubMed
Davis, CL, Kilbourne, AM, Blow, FC, et al. Reduced mortality among Department of Veterans Affairs patients with schizophrenia or bipolar disorder lost to follow-up and engaged in active outreach to return for care. Am J Publ Health 2012; 102(Suppl 1): S74–9.CrossRefGoogle ScholarPubMed
Ganzini, L, Socherman, R, Duckart, J, Shores, M. End-of-life care for veterans with schizophrenia and cancer. Psychiatr Serv 2010; 61: 725–8.CrossRefGoogle ScholarPubMed
Bartels, SJ, DiMilia, PR, Fortuna, KL, Naslund, JA. Integrated care for older adults with serious mental illness and medical comorbidity: evidence-based models and future research directions. Psychiatr Clin N Am 2018; 41(1): 153–64.CrossRefGoogle ScholarPubMed
Druss, BG, Rohrbaugh, RM, Levinson, CM, et al. Integrated medical care for patients with serious psychiatric illness: a randomized trial. Arch Gen Psychiatry 2001; 58(9): 861–8.CrossRefGoogle ScholarPubMed
Saxon, AJ, Malte, CA, Sloan, KL, et al. Randomized trial of onsite versus referral primary medical care for veterans in addictions treatment. Med Care 2006; 44(4): 334–42.CrossRefGoogle ScholarPubMed
Druss, BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry 2007; 68(Suppl 4): 40–4.Google ScholarPubMed
Druss, BG, von Esenwein, SA, Compton, MT, et al. A randomized trial of medical care management for community mental health settings: the primary care access, referral, and evaluation (PCARE) study. Am J Psychiatry 2010; 167(2): 151–9.CrossRefGoogle ScholarPubMed
Druss, BG, von Esenwein, SA, Glick, GE, et al. Randomized trial of an integrated behavioral health home: the health outcomes management and evaluation (HOME) study. Am J Psychiatry 2017; 174(3): 246–55.CrossRefGoogle ScholarPubMed
Pirraglia, PA, Rowland, E, Wu, W-C, et al. Benefits of a primary care clinic co-located and integrated in a mental health setting for veterans with serious mental illness. Prev Chronic Dis 2012; 9: E51.Google Scholar
Pratt, SI, Bartels, SJ, Mueser, KT, et al. Feasibility and effectiveness of an automated telehealth intervention to improve illness self-management in people with serious psychiatric and medical disorders. Psychiatr Rehabil J 2013; 36(4): 297–305.CrossRefGoogle ScholarPubMed
Fortuna, KL, Dimilia, PR, Lohman, MC, et al. Feasibility, acceptability, and preliminary effectiveness of a peer-delivered and technology supported self-management intervention for older adults with serious mental illness. Psychiatr Q. 2018; 89(2): 293–305.CrossRefGoogle ScholarPubMed
Naslund, JA, Aschbrenner, KA, Bartels, SJ. How people living with serious mental illness use smartphones, mobile apps, and social media. Psychiatr Rehabil J 2016; 39(4): 364–7.CrossRefGoogle Scholar
Naslund, JA, Aschbrenner, KA, Marsch, LA, et al. The future of mental health care: peer-to-peer support and social media. Epidemiol Psychiatr Sci 2016; 25(2): 113–22.CrossRefGoogle ScholarPubMed
Naslund, JA, Aschbrenner, KA, McHugo, GJ, et al. Exploring opportunities to support mental health care using social media: a survey of social media users with mental illness. Early Interv Psychiatry 2017: 1–9. doi: 10.1111/eip.12496. [Epub ahead of print]Google ScholarPubMed
Fortuna, KL, Lohman, MC, Batsis, JA, et al. Patient experience with healthcare services among older adults with serious mental illness compared to the general older population. Int J Psychiatry Med 2017; 52(4-6): 381–98.CrossRefGoogle Scholar
De Hert, M, Cohen, D, Bobes, J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011; 10(2): 138–51.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×